Drug Trial Radar · NCT03541668
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
Last checked: Nov 20, 2026Latest source record: Jun 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
674
Actual
Start
May 18, 2018
Primary completion
Apr 14, 2020
Study completion May 24, 2020
Sponsor
- Lead sponsor
- Tasly Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, rt-PA controlled, open-label phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus rt-PA thrombolysis for patients with acute ischaemic stroke in 4.5 hours after stroke onset.
Conditions
- Acute Ischaemic Stroke
Interventions
Recombinant human urokinaseDrug
Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
AlteplaseDrug
Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional handicapTime frame: 90days
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Beijing Luhe Hospital,Capital Medical University
Beijing, Beijing Municipality, China
XuanWu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Liuzhou Worker's Hospital
Liuzhou, Guangxi, China
Cangzhou Central Hospital
Cangzhou, Hebei, China
The First Hospital of Handan
Handan, Hebei, China
Harrison International Peace Hospital
Hengshui, Hebei, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Tangshan Gongren Hospital
Tangshan, Hebei, China
Daqing Oilfield General Hospital
Daqing, Heilongjiang, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Hospital of Changsha
Changsha, Hunan, China
First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Inner Mongolia People's Hospital
Hohhot, Inner Mongolia, China
Huai'an First People's Hospital
Huai'an, Jiangsu, China
The Second People'Hospital of Huai'an
Huai'an, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Jiangxi Pingxiang People's Hospital
Pingxiang, Jiangxi, China
First Hospital of Jilin University
Changchun, Jilin, China
The Neuropsychiatric Hospital of Jilin Province
Siping, Jilin, China
Dalian Municipal Central Hospital
Dalian, Liaoning, China
Shenyang Military Region General Hospital
Shenyang, Liaoning, China
The 163th Hospital of the Chinese People's Liberation Army
Shenyang, Liaoning, China
Liaocheng People's Hospital
Liaocheng, Shandong, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
The People's Hospital of Sichuan Province
Chengdu, Sichuan, China
Deyang people's hospital
Deyang, Sichuan, China
Tianjin Huanhu Hospital
Tianjin, Tianjin Municipality, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Luoyang Central Hospital
Luoyang, Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.